Clinical trial
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
NCT00498966 · AEterna Zentaris, Industry · Completed
Key facts
| NCT number | NCT00498966 |
|---|---|
| Title | Ph II Study of Perifosine for Patients With Carcinoma of the Kidney |
| Official title | Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor |
| Lead sponsor | AEterna Zentaris, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | Perifosine |
| Enrollment | 50 |
| Start date | Jul 1, 2007 |
| Primary completion | Jul 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Jul 11, 2007 |
| Last update posted | Feb 5, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: